DOCSLIB.ORG

Tocris製品30％Offキャンペーン価格表（2021/7/5～2021/8/31）

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

TOCRIS製品30％OFFキャンペーン価格表（2021/7/5～2021/8/31） （メーカーコード順） 希望納⼊価格 キャンペーン価格 コードNo.メーカーコード 英名 容量 (円） (円） 537-31171 0101/100 DL-2-Amino-4-phosphonobutyric Acid [DL-AP4] 100mg 24,000 16,800 - 0102/10 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 10mg 52,000 36,400 - 0102/50 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 50mg 222,000 155,400 - 0103/1 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 1mg 18,000 12,600 531-26804 0103/10 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 10mg 46,000 32,200 533-26803 0103/50 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 50mg 203,000 142,100 - 0104/10 DL-AP7 10mg 30,000 21,000 - 0104/50 DL-AP7 50mg 120,000 84,000 - 0105/10 DL-AP5 10mg 20,000 14,000 530-57943 0105/50 DL-AP5 50mg 81,000 56,700 - 0106/1 D-AP5 1mg 15,000 10,500 531-26843 0106/10 D-AP5 10mg 39,000 27,300 535-26846 0106/100 D-AP5 100mg 235,000 164,500 539-26844 0106/50 D-AP5 50mg 174,000 121,800 - 0107/10 L-AP5 10mg 54,000 37,800 - 0107/50 L-AP5 50mg 235,000 164,500 514-20993 0109/10 (-)-Bicuculline methobromide 10mg 28,000 19,600 518-20991 0109/50 (-)-Bicuculline methobromide 50mg 126,000 88,200 - 0111/1 Dihydrokainic acid 1mg 17,000 11,900 - 0111/10 Dihydrokainic acid 10mg 42,000 29,400 - 0111/50 Dihydrokainic acid 50mg 189,000 132,300 532-28291 0112/50 gamma-D-Glutamylglycine 50mg 38,000 26,600 539-26861 0114/50 N-Methyl-D-aspartic Acid [NMDA] 50mg 24,000 16,800 535-26863 0114/500 N-Methyl-D-aspartic Acid [NMDA] 500mg 100,000 70,000 533-31151 0125/100 DL-AP3 100mg 30,000 21,000 512-21011 0130/50 (+)-Bicuculline 50mg 47,000 32,900 535-57954 0131/10 (-)-Bicuculline Methochloride 10mg 27,000 18,900 531-57956 0131/50 (-)-Bicuculline Methochloride 50mg 119,000 83,300 539-28603 0162/10 S-Sulfo-L-cysteine sodium salt 10mg 50,000 35,000 533-28601 0162/50 S-Sulfo-L-cysteine sodium salt 50mg 217,000 151,900 539-26763 0169/10 (RS)-AMPA 10mg 47,000 32,900 - 0169/50 (RS)-AMPA 50mg 213,000 149,100 - 0173/10 (RS)-CPP 10mg 46,000 32,200 - 0173/50 (RS)-CPP 50mg 191,000 133,700 534-27271 0180/10 ZAPA Sulfate 10mg 28,000 19,600 - 0181/10 TACA 10mg 31,000 21,700 - 0181/50 TACA 50mg 126,000 88,200 537-28361 0183/10 L(-)-threo-3-Hydroxyaspartic Acid 10mg 54,000 37,800 - 0186/10 cis-ACPD 10mg 46,000 32,200 - 0186/50 cis-ACPD 50mg 191,000 133,700 518-23431 0187/10 (+/-)-trans-ACPD 10mg 50,000 35,000 - 0187/50 (+/-)-trans-ACPD 50mg 209,000 146,300 - 0188/1 L-Quisqualic acid 1mg 20,000 14,000 511-23421 0188/10 L-Quisqualic acid 10mg 50,000 35,000 - 0188/50 L-Quisqualic acid 50mg 226,000 158,200 533-51311 0189/10 DNQX 10mg 14,000 9,800 539-51313 0189/50 DNQX 50mg 46,000 32,200 533-26783 0190/10 CNQX 10mg 33,000 23,100 - 0190/50 CNQX 50mg 151,000 105,700 - 0205/1G L-Alanine 1g 14,000 9,800 - 0206/1G b-Alanine 1g 14,000 9,800 - 0208/100 Hypotaurine 100mg 24,000 16,800 - 0209/1G Taurine 1g 14,000 9,800 - 0213/1G D-Aspartic acid 1g 24,000 16,800 534-27933 0216/100 L-Cysteine Sulfinic Acid 100mg 30,000 21,000 - 0217/1G D-Glutamic acid 1g 18,000 12,600 - 0218/1G L-Glutamic acid 1g 14,000 9,800 - 0219/1G Glycine 1g 14,000 9,800 - 0222/1 Kainic acid 1mg 15,000 10,500 533-81743 0222/10 Kainic acid 10mg 39,000 27,300 537-81741 0222/50 Kainic acid 50mg 174,000 121,800 516-47151 0223/1G Kynurenic acid 1g 18,000 12,600 556-17681 0225/1G Quinolinic acid 1g 17,000 11,900 - 0226/1G D-Serine 1g 24,000 16,800 - 0235/100 Isoguvacine hydrochloride 100mg 54,000 37,800 537-27881 0237/10 7-Chlorokynurenic Acid 10mg 24,000 16,800 - 0237/50 7-Chlorokynurenic Acid 50mg 91,000 63,700 536-54961 0238/100 O-Phosphono-L-serine 100mg 17,000 11,900 532-27191 0245/10 2-Hydroxysaclofen 10mg 50,000 35,000 - 0245/50 2-Hydroxysaclofen 50mg 209,000 146,300 532-27211 0246/10 Saclofen 10mg 50,000 35,000 - 0246/50 Saclofen 50mg 209,000 146,300 1 ページ TOCRIS製品30％OFFキャンペーン価格表（2021/7/5～2021/8/31） （メーカーコード順） 希望納⼊価格 キャンペーン価格 コードNo.メーカーコード 英名 容量 (円） (円） - 0247/10 (R)-CPP 10mg 94,000 65,800 - 0247/50 (R)-CPP 50mg 404,000 282,800 - 0254/1 (S)-AMPA 1mg 23,000 16,100 - 0254/10 (S)-AMPA 10mg 57,000 39,900 - 0254/50 (S)-AMPA 50mg 257,000 179,900 538-26711 0258/25 ACBC 25mg 30,000 21,000 - 0281/10 (R)-(+)-HA-966 10mg 38,000 26,600 531-51231 0282/10 (S)-(-)-HA-966 10mg 31,000 21,700 - 0282/50 (S)-(-)-HA-966 50mg 136,000 95,200 534-31181 0284/10 (1S,3R)-ACPD 10mg 57,000 39,900 - 0284/50 (1S,3R)-ACPD 50mg 257,000 179,900 533-54971 0285/5 Ibotenic acid 5mg 79,000 55,300 502-37561 0286/10 5,7-Dichlorokynurenic Acid 10mg 24,000 16,800 508-37563 0286/50 5,7-Dichlorokynurenic Acid 50mg 91,000 63,700 - 0289/1 Muscimol 1mg 18,000 12,600 517-68321 0289/10 Muscimol 10mg 38,000 26,600 - 0289/50 Muscimol 50mg 172,000 120,400 - 0290/250U N-(4-Hydroxyphenylacetyl)spermine 250ug 38,000 26,600 536-51301 0298/10 L-trans-2,4-PDC 10mg 41,000 28,700 - 0298/50 L-trans-2,4-PDC 50mg 184,000 128,800 - 0307/10 (S)-5-Iodowillardiine 10mg 43,000 30,100 - 0307/50 (S)-5-Iodowillardiine 50mg 182,000 127,400 534-32281 0310/10 Carboxyhydroxyphenylglycine, (RS)-, 4, 3, 10mg 46,000 32,200 - 0312/10 (RS)-(Tetrazol-5-yl)glycine 10mg 54,000 37,800 - 0312/50 (RS)-(Tetrazol-5-yl)glycine 50mg 226,000 158,200 - 0323/10 (S)-4-Carboxyphenylglycine 10mg 72,000 50,400 - 0323/50 (S)-4-Carboxyphenylglycine 50mg 308,000 215,600 - 0326/10 (S)-3-Hydroxyphenylglycine 10mg 60,000 42,000 - 0326/50 (S)-3-Hydroxyphenylglycine 50mg 262,000 183,400 - 0328/10 (R)-3-Carboxy-4-hydroxyphenylglycine 10mg 102,000 71,400 - 0328/50 (R)-3-Carboxy-4-hydroxyphenylglycine 50mg 434,000 303,800 532-55041 0332/5 L-CCG-III 5mg 91,000 63,700 - 0333/10 L-CCG-I 10mg 134,000 93,800 535-33311 0336/10 (RS)-MCPG 10mg 36,000 25,200 531-33313 0336/50 (RS)-MCPG 50mg 158,000 110,600 536-51144 0337/10 (S)-MCPG 10mg 68,000 47,600 538-51143 0337/50 (S)-MCPG 50mg 292,000 204,400 - 0342/1 (RS)-3,5-DHPG 1mg 14,000 9,800 539-34931 0342/10 (RS)-3,5-DHPG 10mg 35,000 24,500 535-34933 0342/50 (RS)-3,5-DHPG 50mg 159,000 111,300 - 0344/1G GABA 1g 14,000 9,800 512-75721 0348/10 2-BFI hydrochloride 10mg 38,000 26,600 - 0348/50 2-BFI hydrochloride 50mg 162,000 113,400 - 0351/10 1-Acetyl-4-methylpiperazine Hydrochloride 10mg 28,000 19,600 - 0351/50 1-Acetyl-4-methylpiperazine Hydrochloride 50mg 120,000 84,000 - 0352/10 4-Acetyl-1,1-dimethylpiperazinium Iodide 10mg 28,000 19,600 - 0352/50 4-Acetyl-1,1-dimethylpiperazinium Iodide 50mg 120,000 84,000 - 0355/100 (+/-)-Acetylcarnitine chloride 100mg 17,000 11,900 514-59921 0357/10 N-Acetyltryptamine 10mg 31,000 21,700 - 0357/50 N-Acetyltryptamine 50mg 126,000 88,200 - 0369/100 W-7 hydrochloride 100mg 34,000 23,800 532-51163 0373/10 NBQX 10mg 54,000 37,800 530-51164 0373/50 NBQX 50mg 235,000 164,500 - 0378/10 A-7 hydrochloride 10mg 30,000 21,000 556-88751 0379/10 SKF 97541 10mg 46,000 32,200 - 0379/50 SKF 97541 50mg 191,000 133,700 - 0380/10 Y-25130 Hydrochloride 10mg 41,000 28,700 - 0380/50 Y-25130 Hydrochloride 50mg 184,000 128,800 - 0383/10 Arecaidine propargyl ester tosylate 10mg 27,000 18,900 - 0383/50 Arecaidine propargyl ester tosylate 50mg 108,000 75,600 - 0386/10 3-Methyl-GABA 10mg 30,000 21,000 - 0386/50 3-Methyl-GABA 50mg 127,000 88,900 - 0387/1G (RS)-Atenolol 1g 17,000 11,900 509-24261 0388/10 Ambenonium Dichloride 10mg 33,000 23,100 - 0388/50 Ambenonium Dichloride 50mg 136,000 95,200 - 0389/50 Arcaine sulfate 50mg 31,000 21,700 515-27081 0391/50 Spaglumic acid 50mg 36,000 25,200 537-43021 0395/10 N-Acetylglycyl-D-glutamic Acid 10mg 31,000 21,700 - 0405/10 b-CCB 10mg 27,000 18,900 - 0405/50 b-CCB 50mg 108,000 75,600 - 0411/10 MDL 73005EF Hydrochloride 10mg 38,000 26,600 - 0411/50 MDL 73005EF Hydrochloride 50mg 172,000 120,400 2 ページ TOCRIS製品30％OFFキャンペーン価格表（2021/7/5～2021/8/31） （メーカーコード順） 希望納⼊価格 キャンペーン価格 コードNo.メーカーコード 英名 容量 (円） (円） - 0412/10 MDL 72832 Hydrochloride 10mg 38,000 26,600 - 0412/50 MDL 72832 Hydrochloride 50mg 172,000 120,400 516-20811 0414/10 AG 490 10mg 31,000 21,700 - 0414/50 AG 490 50mg 126,000 88,200 - 0415/50 Ro 20-1724 50mg 17,000 11,900 - 0416/10 YS-035 hydrochloride 10mg 27,000 18,900 - 0416/50 YS-035 hydrochloride 50mg 113,000 79,100 585-79191 0417/1G (RS)-Baclofen 1g 18,000 12,600 519-29061 0420/10 GBR 13069 dihydrochloride 10mg 33,000 23,100 - 0420/50 GBR 13069 dihydrochloride 50mg 136,000 95,200 503-37591 0421/10 GBR 12909 Dihydrochloride 10mg 24,000 16,800 509-37593 0421/50 GBR 12909 Dihydrochloride 50mg 91,000 63,700 - 0424/10 Benzoquinonium dibromide 10mg 33,000 23,100 - 0424/50 Benzoquinonium dibromide 50mg 136,000 95,200 506-37601 0425/10 UK 14,304 10mg 31,000 21,700 502-37603 0425/50 UK 14,304 50mg 126,000 88,200 531-43041 0426/10 L-693.403 maleate 10mg 34,000 23,800 - 0426/50 L-693.403 maleate 50mg 146,000 102,200 577-36511 0427/50 Bromocriptine 50mg 30,000 21,000 - 0431/10 ML 9 hydrochloride 10mg 36,000 25,200 - 0431/50 ML 9 hydrochloride 50mg 153,000 107,100 - 0433/10 SC-9 10mg 38,000 26,600 - 0435/10 Cimaterol 10mg 33,000 23,100 - 0435/50 Cimaterol 50mg 136,000 95,200 - 0438/10 Etazolate hydrochloride 10mg 27,000 18,900 - 0438/50 Etazolate hydrochloride 50mg 108,000 75,600 550-79001 0439/100 DPCPX 100mg 46,000 32,200 537-50971 0440/100 1-(3-Chlorophenyl)biguanide Hydrochloride 100mg 14,000 9,800 - 0442/100 4-Chlorophenylguanidine hydrochloride 100mg 50,000 35,000 - 0443/10 6-Chloromelatonin 10mg 24,000 16,800 - 0443/50 6-Chloromelatonin 50mg 91,000 63,700 514-29371 0444/50 Clozapine 50mg 36,000 25,200 - 0444/500 Clozapine 500mg 191,000 133,700 535-43061 0448/10 Calpeptin 10mg 38,000 26,600 - 0448/50 Calpeptin 50mg 172,000 120,400 - 0452/500 CCCP 500mg 31,000 21,700 588-83231 0453/10 FCCP 10mg 33,000 23,100 - 0453/50 FCCP 50mg 136,000 95,200 539-43101 0454/100 Carbetapentane Citrate 100mg 27,000 18,900 - 0455/25 (S)-(-)-Carbidopa
Recommended publications
  • Multifaceted Physiological Roles of Adiponectin in Inflammation And

    Multifaceted Physiological Roles of Adiponectin in Inflammation And

    International Journal of Molecular Sciences Review Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases Hyung Muk Choi 1, Hari Madhuri Doss 1,2 and Kyoung Soo Kim 1,2,* 1 Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul 02447, Korea; [email protected] (H.M.C.); [email protected] (H.M.D.) 2 East-West Bone & Joint Disease Research Institute, Kyung Hee University Hospital at Gangdong, Gandong-gu, Seoul 02447, Korea * Correspondence: [email protected]; Tel.: +82-2-961-9619 Received: 3 January 2020; Accepted: 10 February 2020; Published: 12 February 2020 Abstract: Adiponectin is the richest adipokine in human plasma, and it is mainly secreted from white adipose tissue. Adiponectin circulates in blood as high-molecular, middle-molecular, and low-molecular weight isoforms. Numerous studies have demonstrated its insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects. Additionally, decreased serum levels of adiponectin is associated with chronic inflammation of metabolic disorders including Type 2 diabetes, obesity, and atherosclerosis. However, recent studies showed that adiponectin could have pro-inflammatory roles in patients with autoimmune diseases. In particular, its high serum level was positively associated with inflammation severity and pathological progression in rheumatoid arthritis, chronic kidney disease, and inflammatory bowel disease. Thus, adiponectin seems to have both pro-inflammatory and anti-inflammatory effects. This indirectly indicates that adiponectin has different physiological roles according to an isoform and effector tissue. Knowledge on the specific functions of isoforms would help develop potential anti-inflammatory therapeutics to target specific adiponectin isoforms against metabolic disorders and autoimmune diseases.
  • Adiporon, an Orally Active, Synthetic Agonist of Adipor1 and Adipor2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice

    Adiporon, an Orally Active, Synthetic Agonist of Adipor1 and Adipor2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice

    molecules Article AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice Hubert Zatorski 1,2, Maciej Salaga 1 , Marta Zieli ´nska 1, Kinga Majchrzak 1, Agata Binienda 1 , Radzisław Kordek 3, Ewa Małecka-Panas 2 and Jakub Fichna 1,4,* 1 Department of Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] (H.Z.); [email protected] (M.S.); [email protected] (M.Z.); [email protected] (K.M.); [email protected] (A.B.) 2 Department of Digestive Tract Diseases, Medical University of Lodz, 93-281 Lodz, Poland; [email protected] 3 Department of Pathology, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] 4 Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland * Correspondence: jakub.fi[email protected]; Tel.: +48-42-272-57-07 Citation: Zatorski, H.; Salaga, M.; Abstract: Introduction: Adiponectin is a hormone secreted by adipocytes, which exhibits insulin- Zieli´nska,M.; Majchrzak, K.; sensitizing and anti-inflammatory properties and acts through adiponectin receptors: AdipoR1 and Binienda, A.; Kordek, R.; AdipoR2. The aim of the study was to evaluate whether activation of adiponectin receptors AdipoR1 Małecka-Panas, E.; Fichna, J. and AdipoR2 with an orally active agonist AdipoRon has gastroprotective effect and to investigate AdipoRon, an Orally Active, the possible underlying mechanism. Methods: We used two well-established mouse models of Synthetic Agonist of AdipoR1 and gastric ulcer (GU) induced by oral administration of EtOH (80% solution in water) or diclofenac AdipoR2 Receptors Has (30 mg/kg, p.o.).
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review

    The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review

    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
  • Research in Your Backyard Developing Cures, Creating Jobs

    Research in Your Backyard Developing Cures, Creating Jobs

    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
  • Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor

    Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor

    molecules Article Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor Tim J. Fyfe 1, Peter J. Scammells 1, J. Robert Lane 2,3,* and Ben Capuano 1,* 1 Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; tim.fyfe@griffithhack.com (T.J.F.); [email protected] (P.J.S.) 2 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia 3 School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK * Correspondence: [email protected] (J.R.L.); [email protected] (B.C.) Abstract: (1) Background: Two first-in-class racemic dopamine D1 receptor (D1R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D1R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (D- and L-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D1R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation Citation: Fyfe, T.J.; Scammells, P.J.; of asymmetric syntheses of optically pure analogues of 2 for the development of D1R PAMs with Lane, J.R.; Capuano, B.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment

    Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment

    University of Kentucky UKnowledge Theses and Dissertations--Neuroscience Neuroscience 2012 DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT Catherine Elizabeth Mattinson University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Mattinson, Catherine Elizabeth, "DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT" (2012). Theses and Dissertations--Neuroscience. 4. https://uknowledge.uky.edu/neurobio_etds/4 This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs

    A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs

    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
  • Human Surrogate Models of Central Sensitization

    Human Surrogate Models of Central Sensitization

    Human surrogate models of central sensitization: a critical review and practical guide Charles Quesada, Anna Kostenko, Idy Ho, Caterina Leone, Zahra Nochi, Alexandre Stouffs, Matthias Wittayer, Ombretta Caspani, Nanna Brix Finnerup, André Mouraux, et al. To cite this version: Charles Quesada, Anna Kostenko, Idy Ho, Caterina Leone, Zahra Nochi, et al.. Human surrogate models of central sensitization: a critical review and practical guide. European Journal of Pain, Wiley, In press, 10.1002/ejp.1768. hal-03196193 HAL Id: hal-03196193 https://hal.archives-ouvertes.fr/hal-03196193 Submitted on 12 Apr 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Human surrogate models of central sensitization: a critical review and practical guide Charles Quesada1,2, Anna Kostenko3, Idy Ho4, Caterina Leone5, Zahra Nochi6, Alexandre Stouffs7, Matthias Wittayer3, Ombretta Caspani3, Nanna Brix Finnerup6, André Mouraux7, Gisèle Pickering8, Irene Tracey4, Andrea Truini5, Rolf-Detlef Treede3, Luis Garcia-Larrea1,2* 1) NeuroPain lab, Lyon Centre for Neuroscience (Inserm
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T

    WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
  • 1 to the Stomach Inhibits Gut-Brain Signalling by the Satiety Hormone Cholecystokinin (CCK)

    1 to the Stomach Inhibits Gut-Brain Signalling by the Satiety Hormone Cholecystokinin (CCK)

    Targeted Expression of Plasminogen Activator Inhibitor (PAI)-1 to the Stomach Inhibits Gut-Brain Signalling by the Satiety Hormone Cholecystokinin (CCK) Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy By Joanne Gamble October 2013 I For Lily, you are the sunshine in my life…. II Table of Contents Figures and tables VII Acknowledgements XI Publications XIII Abstract XIV Chapter 1 ................................................................................................................................ 1 1.1 Overview ........................................................................................................................... 2 1.2 The Gastrointestinal Tract and Digestive Function ...................................................... 4 1.2.1 Distribution, Structure and Biology of Enteroendocrine (EEC) Cells ........................ 5 1.2.2 Luminal Sensing ......................................................................................................... 6 1.3 Energy Homeostasis ......................................................................................................... 7 1.3.1 Gut Hormones ........................................................................................................... 10 1.3.1.1 The Gastrin Family ............................................................................................ 11 1.3.2 PP-fold Family .........................................................................................................